| ￥5700 | |
| Z03970-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||||
| Protein Construction |
|
||||||
| Conjugate | Biotin | ||||||
| Purity |
> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC |
||||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
| Biological Activity | Immobilized VEGF R2/KDR[Biotin], His&Avi, Human (Cat.No.: Z03970) at 0.5 μg/ml (100μl/Well) on the streptavidin precoated plate can bind Anti-VEGF R2 Antibody, hFc Tag | ||||||
| Expression System | HEK293 | ||||||
| Theoretical Molecular Weight | 86.2 kDa | ||||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 115-140 kDa based on Bis-Tris PAGE result. | ||||||
| Formulation | Lyophilized from a 0.22 μm filtered solution in PBS, (pH 7.4). | ||||||
| Reconstitution | It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH2O more than 100 μg/ml. | ||||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of VEGF R2/KDR[Biotin], His & Avi, Human is greater than 95% as determined by SEC-HPLC. »
VEGF R2/KDR[Biotin], His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
Immobilized VEGF R2/KDR[Biotin], His & Avi, Human at 0.5 μg/ml (100 μl/Well) on streptavidin(5 μg/ml) precoated plate. Dose response curve for Anti-VEGF R2 Antibody, hFc Tag with the EC50 of 2.6 ng/ml determined by ELISA. »
Serial dilutions of Anti-VEGF165 Antibody were added into Human VEGF165, No Tag : VEGF R2/KDR[Biotin], His&Avi, Human, His Avi Tag binding reactioins. The half maximal inhibitiory concentration(IC50) is 0.30 mg/ml. »
Immobilized Human VEGF165, No Tag at 5 mg/ml (100 mI/well) on the plate. Dose response curve for VEGF R2/KDR[Biotin], His&Avi, Human, His-Avi Tag with the EC50 of 1.27 mg/ml determined by ELISA. »
| Target Background | Vascular endothelial growth factor receptor 2 (VEGFR2) is one kind of tyrosine kinase receptors. VEGFR2 acts as a cell-surface receptor for VEGFA, VEGFB and PGF. It plays an important role in the development of embryonic vasculature, cell survival and cancer cell invasion. VEGFR2 is a key regulator of angiogenesis. |
| Synonyms | CD309; KDR; VEGFR; VEGFR2; VEGFR-21; FLK1; KRD1; Ly73 |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
